Obesity and Clozapine Use in Schizophrenia
DOI:
https://doi.org/10.17140/OROJ-3-124Keywords:
Schizophrenia; Clozapine; ObesityAbstract
Introduction: Schizophrenia is a chronic mental disorder, and treatment is based on the use of
antipsychotics, such as clozapine. These drugs have been associated with obesity and metabolic
changes.
Objective: A systematic review to assess the association of obesity with the use of clozapine in
schizophrenic patients.
Method: It was made a search for articles in PUBMED and Capes of the regular databases with
the keywords “Schizophrenia” “obesity” “clozapine” “weight gain”. The search included articles in English that were published between 2004 and 2015. We included only articles with retrospective studies and the following inclusion criteria: both sexes, patients older than 20 years,
use of time of clozapine minimum of three months and sample size less than 50 individuals.
Results: They were selected 4 articles contemplated the inclusion criteria. In all items selected
for this study, obesity was associated with clozapine.
Conclusions: There is a higher prevalence of overweight and obesity in patients with schizophrenia compared with the general population, this is due to some factors such as the use of
atypical antipsychotics, such as clozapine.
References
Mari JJ, Leitão RJ. A epidemiologia da esquizofrenia [In Por-tuguese]. Rev Bras Psiquiatr. 2000; 22(1): 15-17. doi: 10.1590/ S1516-44462000000500006
DSM-IV. Manual Diagnóstico e Estatístico de Transtornos Mentais [In Portuguese]. 4th ed. Porto Alegre, Brazil: Artes Médicas; 1995. Web site. http://c026204.cdn.sapo.io/1/c026204/ Outcomes th week 2 and in the 56th week of 2.67 kg/ nd ) was present in 38% of patients and clo-st generation (5.4%). Patients were more likely to become obese cld-file/1426522730/6d77c9965e17b15/b37dfc58aad8cd-477904b9bb2ba8a75b/obaudoeducador/2015/DSM%20V.pdf. Accessed May 22, 2016
Kaiser S, Heekeren K, Simon JJ. The negative symptoms of schizophrenia: Category or continuum? Psychopathology. 2010; 44: 345-353. doi: 10.1159/000325912
Oliveira IR. Antipsicóticos atípicos: Farmacologia e uso clínico [In Portuguese]. Rev Bras Psiquiatr. 2000; 22(1). doi: 10.1590/S1516-44462000000500013
Zortéa K, Bock PM, Moreno DB, Belmonte de Abreu PS. Avaliação antropométrica e bioquímica em pacientes com es-quizofrenia usuários de clozapina [In Portuguese]. Rev Nutr. 2009; 22(5): 697-705. Web site. http://www.lume.ufrgs.br/ handle/10183/69895. Accessed May 22, 2016.
Leitão-Azevedo CL, Guimarães LR, Lobato MI. Ganho de peso e alterações metabólicas em esquizofrenia [In Portuguese]. Rev Psiquiatr Clin. 2007; 34(2): 184-188. Web site. http://www. lume.ufrgs.br/handle/10183/20468. Accessed May 22, 2016
Mojtaba IR, Nicholson RA, Carpenter BN. Role of psychoso-cial treatments in management of schizophrenia: A meta-analyt-ic review of controlled outcome estudies. Schizophr Bull. 1998; 24(4): 569-587. Web site. http://schizophreniabulletin.oxford-journals.org/content/24/4/569.long. Accessed May 22, 2016
Francischi RPP, Pereira LO, Freitas CS, et al. Obesity: updated information about its etiology, morbidity and treatment. Rev Nutr. 2000; 13(1): 17-28. doi: 10.1590/S1415-52732000000100003
Ministerio da Saude. Prevalência Obesidade [In Portuguese]. Web site. http://portal.saude.gov.br/404.html. Accessed May 22, 2016
Pesquisa de Orçamentos Familiares 2008-2009. Antropome-tria e estado nutricional de crianças, adolescentes e adultos no Brasil [In Portuguese]. Web site. http://www.ibge.gov.br/home/ estatistica/populacao/condicaodevida/pof/2008_2009_encaa/. Accessed May 22, 2016
Villanueva API , Romero A, Goti J, et al. Should obesity be a limiting factor for clozapine treatment? Rev Psiquiatr Salud Ment. 6(2): 75-79. doi: 10.1016/j.rpsm.2012.05.005
Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-in-duced weight gain and other metabolic complications in a swiss psychiatric population. J Psychiatr Res. 2012; 46(4): 540-548. doi: 10.1016/j.jpsychires.2012.01.014
Bai YM, Lin C-C, Chen J-Y, Lin C-Y, Su T-P, Chou P. As-sociation of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry. 2006; 163: 1276- 1279. Web site. http://ajp.psychiatryonline.org/doi/pdf/10.1176/ ajp.2006.163.7.1276. Accessed May 22, 2016
Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medica-tions. Schizophr Bull. 2004; 30(2): 229-240. Web site. http:// schizophreniabulletin.oxfordjournals.org/content/30/2/229.full. pdf. Accessed May 22, 2016
Garn SM, Leonard WR, Hawthorne VM. Three limitations of the body mass index. Am J Clin Nutr. 1986; 44(6): 996-997. Web site. http://ajcn.nutrition.org/content/44/6/996.long. Ac-cessed May 22, 2016
Cervi A, Franceschini SC, Priore SE. Critical analysis of the use of the body mass index for the elderly. Rev Nutr. 2005; 18(6). doi: 10.1590/S1415-52732005000600007
Grupta S, Droney T, AL-Samarrai S, Keller P, Frank B. Olan-zapine: Weight gain and therapeutic efficacy. J Clin Psycho-pharmacol. 1999; 19(3): 273-275. Web site. http://www.ncbi. nlm.nih.gov/pubmed/10350036. Accessed May 22, 2016
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Obesity Research (OR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
